# Shasqi

> Shasqi is a San Francisco biotechnology company developing cancer therapies that use in vivo click chemistry to reunite a tumor-targeting component with a separately delivered drug payload. Its first candidate, SQ3370, demonstrated clinical proof of concept and dose tolerance but its phase 2a sarcoma cohort stopped after missing a prespecified response threshold; the company is pursuing antigen-targeted follow-on programs.

- **Founded:** 2015
- **Headquarters:** San Francisco, United States
- **Founders:** José M. Mejía Oneto (Founder and CEO)
- **Products:** CAPAC platform, SQ3370, CEACAM5-targeted MMAE program, SQP22 platform payload
- **Notable:** First reported clinical use of in vivo click chemistry in humans with SQ3370., Peer-reviewed 2025 Clinical Cancer Research paper on preclinical translation and phase 1 dose escalation., Phase 1 tested up to 15 times conventional doxorubicin-equivalent dosing without reported dose-limiting toxicities.

## Products & services

- **CAPAC platform** — Click Activated Protodrugs Against Cancer: modular pre-targeting system that pairs a tumor-localized clickable binder with a separately administered clickable drug or radioisotope.
- **SQ3370** — Clinical-stage experimental combination of intratumorally injected SQL70 biopolymer and intravenous SQP33 doxorubicin protodrug; phase 1/2a study terminated after missing its prespecified continuation criterion.
- **CEACAM5-targeted MMAE program** — Preclinical antigen-targeted clickable antibody fragment paired with SQP22, an attenuated MMAE payload; the company identifies this as its next lead asset.
- **SQP22 platform payload** — Clickable MMAE protodrug investigated with HER2, CEACAM5 and other tumor-targeting binders in preclinical models.

## Achievements

- First reported clinical use of in vivo click chemistry in humans with SQ3370.
- Peer-reviewed 2025 Clinical Cancer Research paper on preclinical translation and phase 1 dose escalation.
- Phase 1 tested up to 15 times conventional doxorubicin-equivalent dosing without reported dose-limiting toxicities.
- Expanded research collaboration with Johnson & Johnson Enterprise Innovation in 2023.

## Latest updates

- **2026-04** — AACR 2026 proceedings included a preclinical abstract on CEACAM5-targeted click chemistry activation of MMAE.
- **2025-11** — Presented a CEACAM5 pre-targeting poster at World ADC San Diego.
- **2025-10** — Appointed former Pfizer Oncology and Seagen executive Roger Dansey to its board.
- **2025-06** — Published a Clinical Cancer Research paper on SQ3370 development and first-in-human testing.

## Links

- Website: https://www.shasqi.com/
- LinkedIn: https://www.linkedin.com/company/shasqi-inc-/
- Twitter/X: https://x.com/shasqi

---

Profile page: https://yespress.io/shasqi
Published by YesPress — https://yespress.io
Last updated: 2026-09-29